Allon trial studies pharmacokinetics of AL-108 & AL-208
- Category: Proteins and Peptides
- Published on Friday, 11 January 2008 02:34
- Hits: 1527
Allon Therapeutics Inc. announced today that it had commenced dosing in a Phase I clinical trial to evaluate the pharmacokinetics of AL-108 (intranasal administration) or AL-208 in the blood and cerebrospinal fluid (CSF) of healthy adult subjects
VANCOUVER, Canada | January 10, 2008 | Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, announced today that it had commenced dosing in a Phase I clinical trial to evaluate the pharmacokinetics of AL-108 (intranasal administration) or AL-208 (intravenous administration) in the blood and cerebrospinal fluid (CSF) of healthy adult subjects.
Gordon McCauley, Allon's President and CEO, said the trial will complement the safety, tolerability and efficacy data from three Phase II human clinical trials from which Allon will release results during 2008. Results from the Phase I trial will be used to optimize design of the next stage of clinical trials for AL-108 and AL-208. The Phase I trial will also supplement extensive animal data on the pharmacokinetics of AL-108 and AL-208.
“Positive results from the three Phase II trials would establish AL-108 and AL-208 as the first drugs under development to demonstrate in patients an impact on the mechanisms that lead to physical damage in the brain,” said McCauley.
“This Phase I trial will study how the human body handles our drugs after either intranasal or intravenous administration. In particular, we will obtain a better understanding of the rate at which our drug moves through the bloodstream and into the brain. ” said McCauley. A total of 18 subjects will participate in the open label, trial examining various doses after a single administration.
AL-108 is being evaluated in a Phase II trial in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease (AD), and in a Phase II trial in cognitive impairment associated with schizophrenia (CIAS).
AL-208 is being evaluated in a Phase II trial as a prevention for the mild cognitive impairment (MCI) resulting from ischemic damage during coronary bypass graft surgery (CABG). Trial results will also indicate AL-208’s potential as a treatment for the ischemic damage resulting from stoke.
Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon has three Phase II human efficacy trials under way pursuing three large underserved markets: Alzheimer's disease, stroke and cognitive impairment associated with schizophrenia. The Company is listed on the Toronto Stock Exchange under the trading symbol "NPC" (Neuroprotection CompanyTM) and based in Vancouver. For additional information please visit the Company's website: www.allontherapeutics.com.
Forward Looking Statements
There are forward-looking statements contained herein that are not based on historical fact, including without limitation statements containing the words "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, Allon's stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market Allon's products, the ability to protect its intellectual property and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments.
SOURCE: ALLON THERAPEUTICS